Sporotrichosis
Solutions
Online Inquiry

Sporotrichosis

Sporotrichosis, a fungal infection instigated by the pathogen Sporothrix species, is attributed to the dimorphic fungus Sporothrix schenckii. Distinguishing itself in the realm of uncommon diseases like sporotrichosis, our company excels by providing all-encompassing, specialized services designed for researchers and scientists involved in this unique field.

Overview of Sporotrichosis

Sporotrichosis is mainly a type of subcutaneous mycosis, impacting the skin, subcutaneous tissue, and lymphatic system. The usual mode of transmission involves the accidental introduction of the fungus into the skin through trauma, frequently from coming into contact with tainted plant matter or soil. Moreover, acquiring this infection through scratches or bites from infected animals is another common avenue. Sporotrichosis presents in two primary forms: cutaneous sporotrichosis and extracutaneous sporotrichosis.

Agents of human and animal sporotrichosis.Fig.1 Phylogenetic analysis of the main members of medical relevance in the genus Sporothrix. (Rodrigues, A. M., et al., 2022)

Pathogenesis of Sporotrichosis

Sporotrichosis, a fungal infection primarily triggered by the dimorphic fungus Sporothrix schenckii and its related species, is prevalent in vegetation worldwide, decaying organic material, Sphagnum moss, and soil. This fungus infiltrates the body through skin breaks, often resulting in a minor, painless bump at the entry point. The infection can progress along the lymphatic vessels, causing a series of nodules or ulcers. In certain instances, particularly in individuals with weakened immune systems, the infection may disseminate to other organs like bones, joints, and lungs.

Drug targets of sporotrichosis.Fig.2 The main antifungal agents and their cellular targets. (Rodrigues, A. M., et al., 2022)

Vaccine and Therapeutic Development for Sporotrichosis

Types Names Mechanism of Action Targets Research Phase
Vaccine development MAb P6E7 A monoclonal antibody against cell wall Gp70 glycoprotein Gp70 glycoprotein Preclinical research
ZR8 peptide Induce the cellular immune response GP60-70 protein Preclinical research
PGA+CWP100 Increase anti-ssCWP IgG, IgG1, IgG2a, and IgG3 levels ssCWP Preclinical research
Therapeutic development Potassium iodide Inhibit biofilm development in Sporothrix / Approved
Itraconazole Inhibit the synthesis of ergosterol CYP51A1 Approved
Terbinafine Inhibitor of ergosterol synthesis SQLE Approved
TCAN26 Cell membrane disruption / Preclinical research
Buparvaquone Mitochondrial dysfunction / Preclinical research
Miltefosine Cell membrane disruption CCT Approved

Our Services

Our company has advanced infectious disease models, and vaccine and therapeutic development platforms, and excels in providing a seamless service for professionals seeking to delve into the intricacies of rare diseases. From access to cutting-edge laboratory facilities to expert consultation services, we ensure that researchers have all the necessary tools at their disposal to advance their studies on diseases like sporotrichosis.

Featured Services for Sporotrichosis

By offering a centralized hub of resources and expertise, we empower researchers and scientists to make significant strides in understanding and combating diseases such as sporotrichosis. If you are interested in availing of our services, please do not hesitate to reach out to us for more details and quotations related to our offerings.

References

  1. Rodrigues, Anderson Messias et al. "Current Progress on Epidemiology, Diagnosis, and Treatment of Sporotrichosis and Their Future Trends." Journal of fungi (Basel, Switzerland) 8.8 (2022): 776.
  2. Sharma, Bunty et al. "Sporotrichosis: a Comprehensive Review on Recent Drug-Based Therapeutics and Management." Current dermatology reports 11.2 (2022): 110-119.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.